Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Popovici
Cornel
C
Laboratoire d'Oncologie Moléculaire, INSERM UMR599 et Institut Paoli-Calmettes, Marseille, France.
Charbonnier
Aude
A
Gisserot
Olivier
O
Aguilon
Philippe
P
Rémy
Virginie
V
Olschwang
Sylviane
S
Mozziconacci
Marie-Joëlle
MJ
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013844:Thiazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib